These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21624734)

  • 1. Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction.
    Weir RA; Clements S; Steedman T; Dargie HJ; McMurray JJ; Squire IB; Ng LL
    J Card Fail; 2011 Jun; 17(6):465-71. PubMed ID: 21624734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Dhillon O; Narayan H; Ng KH; Quinn P; Davies JE; Ng LL
    Am J Cardiol; 2010 Aug; 106(4):477-82. PubMed ID: 20691304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
    Nilsson L; Hallén J; Atar D; Jonasson L; Swahn E
    Heart; 2012 Jan; 98(1):31-6. PubMed ID: 21727201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?
    Weir RA; Miller AM; Petrie CJ; Clements S; Steedman T; Dargie HJ; Squire IB; Ng LL; McInnes IB; McMurray JJ
    Cytokine; 2012 Oct; 60(1):220-5. PubMed ID: 22748465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy.
    Franz M; Berndt A; Altendorf-Hofmann A; Fiedler N; Richter P; Schumm J; Fritzenwanger M; Figulla HR; Brehm BR
    Eur J Heart Fail; 2009 Nov; 11(11):1057-62. PubMed ID: 19815660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
    Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
    Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.
    Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC
    Am J Cardiol; 2005 Jul; 96(1):31-4. PubMed ID: 15979428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive utility of the changes in matrix metalloproteinase-2 in the early phase for left ventricular reverse remodeling after an acute myocardial infarction.
    Morishita T; Uzui H; Mitsuke Y; Arakawa K; Amaya N; Kaseno K; Ishida K; Nakaya R; Lee JD; Tada H
    J Am Heart Assoc; 2015 Jan; 4(1):e001359. PubMed ID: 25616975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
    Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):53-61. PubMed ID: 15782494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
    Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
    J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
    Hudson MP; Armstrong PW; Ruzyllo W; Brum J; Cusmano L; Krzeski P; Lyon R; Quinones M; Theroux P; Sydlowski D; Kim HE; Garcia MJ; Jaber WA; Weaver WD
    J Am Coll Cardiol; 2006 Jul; 48(1):15-20. PubMed ID: 16814643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial.
    Cerisano G; Buonamici P; Gori AM; Valenti R; Sciagrà R; Giusti B; Sereni A; Raspanti S; Colonna P; Gensini GF; Abbate R; Schulz R; Antoniucci D
    Int J Cardiol; 2015 Oct; 197():147-53. PubMed ID: 26134371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients?
    Oren H; Erbay AR; Balci M; Cehreli S
    Angiology; 2007; 58(1):45-54. PubMed ID: 17351157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of left ventricular dyssynchrony after acute myocardial infarction, assessed by a tagging magnetic resonance image derived metric, as a determinant of ventricular remodeling.
    Chang SA; Chang HJ; Choi SI; Chun EJ; Yoon YE; Kim HK; Kim YJ; Choi DJ; Sohn DW; Helm RH; Lardo AC
    Am J Cardiol; 2009 Jul; 104(1):19-23. PubMed ID: 19576315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Quinn P; Struck J; Morgenthaler NG; Davies JE; Ng LL
    J Card Fail; 2008 Nov; 14(9):739-45. PubMed ID: 18995178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: an animal experiment with rats].
    Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1288-93. PubMed ID: 15387968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction.
    Tian H; Cimini M; Fedak PW; Altamentova S; Fazel S; Huang ML; Weisel RD; Li RK
    J Mol Cell Cardiol; 2007 Dec; 43(6):733-43. PubMed ID: 17945252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.